Icecure Medical (ICCM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IceCure Medical’s ProSense® system has been highlighted for its 100% success rate in destroying breast tumors ≤ 25mm in a study of patients who opted for cryoablation over surgery. The study, published in the British Journal of Radiology, demonstrates cryoablation as a safe, effective outpatient alternative to surgery, particularly favored by the elderly. These results may indicate a growing demand for IceCure’s non-surgical treatment option in light of an aging population at increased risk for breast cancer.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.